Eyegate pharmaceuticals, inc. EYEG.US Overview
EYEG AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
EYEG Current Performance
0.20%
Eyegate pharmaceuticals, inc.
-0.78%
Avg of Sector
-0.01%
S&P500
EYEG Key Information
EYEG Revenue by Segments
Browsing restrictions can be lifted for a fee.
EYEG Net Income
Browsing restrictions can be lifted for a fee.
EYEG Cash Flow
Browsing restrictions can be lifted for a fee.
EYEG Profit Margin
Browsing restrictions can be lifted for a fee.
EYEG PE Ratio River
Browsing restrictions can be lifted for a fee.
EYEG Financial Forecast
Browsing restrictions can be lifted for a fee.
EYEG Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
EYEG Profile
EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. The company is headquartered in Waltham, Massachusetts and currently employs 11 full-time employees. The firm is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The firm's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The firm is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.
Price of EYEG
EYEG FAQ
When is EYEG's latest earnings report released?
The most recent financial report for Eyegate pharmaceuticals, inc. (EYEG) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating EYEG's short-term business performance and financial health. For the latest updates on EYEG's earnings releases, visit this page regularly.
How much debt does EYEG have?
As of the end of the reporting period, Eyegate pharmaceuticals, inc. (EYEG) had total debt of 159.02K, with a debt ratio of 0. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does EYEG have?
At the end of the period, Eyegate pharmaceuticals, inc. (EYEG) held Total Cash and Cash Equivalents of 3.77M, accounting for 0.11 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
What are the PEG ratio and PE ratio of EYEG?
The latest valuation data shows Eyegate pharmaceuticals, inc. (EYEG) has a Price-To-Earnings (PE) ratio of -11.41 and a Price/Earnings-To-Growth (PEG) ratio of -0.22. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.